Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens
Background Flow cytometry (FC) is a popular method to detect bone marrow (BM) involvement in patients with B-cell non-Hodgkin lymphoma (B-NHL). The majority of screen panels of FC still rely on finding monoclonal B-cells, e.g., B-cells with immunoglobin (Ig) light-chain restriction, which has many l...
Gespeichert in:
| Veröffentlicht in: | BMC cancer 2021-12, Vol.21 (1), p.1315-1315, Article 1315 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1315 |
|---|---|
| container_issue | 1 |
| container_start_page | 1315 |
| container_title | BMC cancer |
| container_volume | 21 |
| creator | Wang, Wei Li, Yan Ali, Haval Zhao, Linjun Mei, Di Hu, Wenqing Jiang, Bin |
| description | Background Flow cytometry (FC) is a popular method to detect bone marrow (BM) involvement in patients with B-cell non-Hodgkin lymphoma (B-NHL). The majority of screen panels of FC still rely on finding monoclonal B-cells, e.g., B-cells with immunoglobin (Ig) light-chain restriction, which has many limitations. Therefore, exploring new markers is warranted. Methods A total of 52 cases of B-NHL with BM involvement were collected. The median age was 60 years. Out of these 52 cases, 34 were male, and 18 were female. A 10-color FC panel was used to detect the expression of CD54 on lymphoma cells. The expression of CD54 was calculated as the mean fluorescence index ratio (MFIR) and was described as the mean +/- standard error of the mean (SEM). Results Up to 18/52 (34.62%) of BM specimens abnormally expressed an increased level of CD54, including 1/10 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 9/13 cases of mantle cell lymphoma (MCL), 2/14 cases of follicular lymphoma (FL), 5/9 cases of marginal zone lymphoma (MZL), and 1/3 cases of high-grade B-NHL (HG B-NHL). The expression level of CD54 was significantly increased in MCL cases (53.41 +/- 11.04) compared with CLL/SLL cases (11.66 +/- 2.79) and FL cases (13.49 +/- 2.81). The lowest percentage of CD54-positive B-cells attained 0.13%. In 5/9 cases of MZL and 1/3 cases of HG B-NHL, increased expression of CD54 was the only abnormal immunophenotype detected besides Ig light-chain restriction. No aberrant CD54 expression was identified by FC in lymphoplasmacytic lymphoma (LPL) (0/2) and Burkitt lymphoma (BL) (0/1) cases. Aberrant expression of CD54 was not related to plasma cell differentiation. Conclusion Lymphoma cells, especially in MCL and MZL cases, frequently show increased expression of CD54. Such aberrant expression is not related to plasma cell differentiation. We highly recommend adding CD54 to the FC screening panel to detect BM involvement in patients with B-NHL. |
| doi_str_mv | 10.1186/s12885-021-09061-3 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_gale_healthsolutions_A686420553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A686420553</galeid><doaj_id>oai_doaj_org_article_adf3429948024a8a88c738d536749542</doaj_id><sourcerecordid>A686420553</sourcerecordid><originalsourceid>FETCH-LOGICAL-c628t-9bc12e3925e392281d114f454fc3a45f0da48067c1110cf499bb5f53f3a24df43</originalsourceid><addsrcrecordid>eNqNkl2L1DAUhoso7rr6B7yQgCCKdM1nm94I6_g1sCD4cR3S9GQmS9uMSeru_HvTnXWYES9soSnJ8745OXmL4inB54TI6k0kVEpRYkpK3OCKlOxecUp4TUrKcX3_4P-keBTjFcakllg-LE4Yl3UjaXVaXF-0EIIeE4KbTYAYnR-Rt2jxXnDUQQKToEPtFtneXyOzTX6AFLbIRaSRWeugMxBcTM7Msndlvx02az_kRej7iNyIWj8CGnQI2SBuwLgBxvi4eGB1H-HJ3XhW_Pj44fvic3n55dNycXFZmorKVDatIRRYQ8X8oZJ0hHDLBbeGaS4s7jSXuKoNIQQby5umbYUVzDJNeWc5OyuWO9_O6yu1CS4XslVeO3U74cNK6ZCL70HpzjJOmyYbUq6lltLUTHaCVTVvBKfZ6-3OazO1A3QGxhR0f2R6vDK6tVr5X0pWggk5G7y8Mwj-5wQxqcHFuU96BD9FRSvc8AoLjjP6_C_0yk9hzK3KFCGMMFkfUCudD-BG6_O-ZjZVF5WsOMVCsEyd_4PKbweDM_l2rMvzR4JXR4LMJLhJKz3FqJbfvh6zLw7YNeg-raPvp5SDFI9BugNN8DEGsPvGEazmPKtdnlXOs7rNs5pFzw5bvpf8CXAGXu-Aa2i9jcbBaGCPYYzrHJo6X2l-SKbl_9MLl_R8ioWfxsR-AzGuDZA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2611313870</pqid></control><display><type>article</type><title>Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><creator>Wang, Wei ; Li, Yan ; Ali, Haval ; Zhao, Linjun ; Mei, Di ; Hu, Wenqing ; Jiang, Bin</creator><creatorcontrib>Wang, Wei ; Li, Yan ; Ali, Haval ; Zhao, Linjun ; Mei, Di ; Hu, Wenqing ; Jiang, Bin</creatorcontrib><description>Background Flow cytometry (FC) is a popular method to detect bone marrow (BM) involvement in patients with B-cell non-Hodgkin lymphoma (B-NHL). The majority of screen panels of FC still rely on finding monoclonal B-cells, e.g., B-cells with immunoglobin (Ig) light-chain restriction, which has many limitations. Therefore, exploring new markers is warranted. Methods A total of 52 cases of B-NHL with BM involvement were collected. The median age was 60 years. Out of these 52 cases, 34 were male, and 18 were female. A 10-color FC panel was used to detect the expression of CD54 on lymphoma cells. The expression of CD54 was calculated as the mean fluorescence index ratio (MFIR) and was described as the mean +/- standard error of the mean (SEM). Results Up to 18/52 (34.62%) of BM specimens abnormally expressed an increased level of CD54, including 1/10 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 9/13 cases of mantle cell lymphoma (MCL), 2/14 cases of follicular lymphoma (FL), 5/9 cases of marginal zone lymphoma (MZL), and 1/3 cases of high-grade B-NHL (HG B-NHL). The expression level of CD54 was significantly increased in MCL cases (53.41 +/- 11.04) compared with CLL/SLL cases (11.66 +/- 2.79) and FL cases (13.49 +/- 2.81). The lowest percentage of CD54-positive B-cells attained 0.13%. In 5/9 cases of MZL and 1/3 cases of HG B-NHL, increased expression of CD54 was the only abnormal immunophenotype detected besides Ig light-chain restriction. No aberrant CD54 expression was identified by FC in lymphoplasmacytic lymphoma (LPL) (0/2) and Burkitt lymphoma (BL) (0/1) cases. Aberrant expression of CD54 was not related to plasma cell differentiation. Conclusion Lymphoma cells, especially in MCL and MZL cases, frequently show increased expression of CD54. Such aberrant expression is not related to plasma cell differentiation. We highly recommend adding CD54 to the FC screening panel to detect BM involvement in patients with B-NHL.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-021-09061-3</identifier><identifier>PMID: 34879826</identifier><language>eng</language><publisher>LONDON: Springer Nature</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Analysis ; B cells ; B-cell non-Hodgkin lymphoma ; Biopsy ; Bone marrow ; Bone Marrow Cells - chemistry ; Bone Marrow Cells - metabolism ; Bone marrow examination ; Bone marrow involvement ; Burkitt's lymphoma ; Care and treatment ; CD54 ; Cell differentiation ; Chronic lymphocytic leukemia ; Complications and side effects ; Diagnosis ; Female ; Flow Cytometry ; Humans ; Immunoglobulins ; Intercellular Adhesion Molecule-1 - analysis ; Intercellular Adhesion Molecule-1 - metabolism ; Life Sciences & Biomedicine ; Light ; Lymphatic leukemia ; Lymphocytes B ; Lymphoma ; Lymphoma, B-Cell - metabolism ; Lymphoma, B-Cell - pathology ; Male ; Mantle cell lymphoma ; Measurement ; Middle Aged ; Non-Hodgkin's lymphoma ; Non-Hodgkin's lymphomas ; Oncology ; Plasma ; Science & Technology ; Statistical analysis ; Variance analysis</subject><ispartof>BMC cancer, 2021-12, Vol.21 (1), p.1315-1315, Article 1315</ispartof><rights>2021. The Author(s).</rights><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>3</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000728174800001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c628t-9bc12e3925e392281d114f454fc3a45f0da48067c1110cf499bb5f53f3a24df43</citedby><cites>FETCH-LOGICAL-c628t-9bc12e3925e392281d114f454fc3a45f0da48067c1110cf499bb5f53f3a24df43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653582/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653582/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2115,27929,27930,39263,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34879826$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Ali, Haval</creatorcontrib><creatorcontrib>Zhao, Linjun</creatorcontrib><creatorcontrib>Mei, Di</creatorcontrib><creatorcontrib>Hu, Wenqing</creatorcontrib><creatorcontrib>Jiang, Bin</creatorcontrib><title>Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens</title><title>BMC cancer</title><addtitle>BMC CANCER</addtitle><addtitle>BMC Cancer</addtitle><description>Background Flow cytometry (FC) is a popular method to detect bone marrow (BM) involvement in patients with B-cell non-Hodgkin lymphoma (B-NHL). The majority of screen panels of FC still rely on finding monoclonal B-cells, e.g., B-cells with immunoglobin (Ig) light-chain restriction, which has many limitations. Therefore, exploring new markers is warranted. Methods A total of 52 cases of B-NHL with BM involvement were collected. The median age was 60 years. Out of these 52 cases, 34 were male, and 18 were female. A 10-color FC panel was used to detect the expression of CD54 on lymphoma cells. The expression of CD54 was calculated as the mean fluorescence index ratio (MFIR) and was described as the mean +/- standard error of the mean (SEM). Results Up to 18/52 (34.62%) of BM specimens abnormally expressed an increased level of CD54, including 1/10 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 9/13 cases of mantle cell lymphoma (MCL), 2/14 cases of follicular lymphoma (FL), 5/9 cases of marginal zone lymphoma (MZL), and 1/3 cases of high-grade B-NHL (HG B-NHL). The expression level of CD54 was significantly increased in MCL cases (53.41 +/- 11.04) compared with CLL/SLL cases (11.66 +/- 2.79) and FL cases (13.49 +/- 2.81). The lowest percentage of CD54-positive B-cells attained 0.13%. In 5/9 cases of MZL and 1/3 cases of HG B-NHL, increased expression of CD54 was the only abnormal immunophenotype detected besides Ig light-chain restriction. No aberrant CD54 expression was identified by FC in lymphoplasmacytic lymphoma (LPL) (0/2) and Burkitt lymphoma (BL) (0/1) cases. Aberrant expression of CD54 was not related to plasma cell differentiation. Conclusion Lymphoma cells, especially in MCL and MZL cases, frequently show increased expression of CD54. Such aberrant expression is not related to plasma cell differentiation. We highly recommend adding CD54 to the FC screening panel to detect BM involvement in patients with B-NHL.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>B cells</subject><subject>B-cell non-Hodgkin lymphoma</subject><subject>Biopsy</subject><subject>Bone marrow</subject><subject>Bone Marrow Cells - chemistry</subject><subject>Bone Marrow Cells - metabolism</subject><subject>Bone marrow examination</subject><subject>Bone marrow involvement</subject><subject>Burkitt's lymphoma</subject><subject>Care and treatment</subject><subject>CD54</subject><subject>Cell differentiation</subject><subject>Chronic lymphocytic leukemia</subject><subject>Complications and side effects</subject><subject>Diagnosis</subject><subject>Female</subject><subject>Flow Cytometry</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Intercellular Adhesion Molecule-1 - analysis</subject><subject>Intercellular Adhesion Molecule-1 - metabolism</subject><subject>Life Sciences & Biomedicine</subject><subject>Light</subject><subject>Lymphatic leukemia</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Lymphoma, B-Cell - metabolism</subject><subject>Lymphoma, B-Cell - pathology</subject><subject>Male</subject><subject>Mantle cell lymphoma</subject><subject>Measurement</subject><subject>Middle Aged</subject><subject>Non-Hodgkin's lymphoma</subject><subject>Non-Hodgkin's lymphomas</subject><subject>Oncology</subject><subject>Plasma</subject><subject>Science & Technology</subject><subject>Statistical analysis</subject><subject>Variance analysis</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl2L1DAUhoso7rr6B7yQgCCKdM1nm94I6_g1sCD4cR3S9GQmS9uMSeru_HvTnXWYES9soSnJ8745OXmL4inB54TI6k0kVEpRYkpK3OCKlOxecUp4TUrKcX3_4P-keBTjFcakllg-LE4Yl3UjaXVaXF-0EIIeE4KbTYAYnR-Rt2jxXnDUQQKToEPtFtneXyOzTX6AFLbIRaSRWeugMxBcTM7Msndlvx02az_kRej7iNyIWj8CGnQI2SBuwLgBxvi4eGB1H-HJ3XhW_Pj44fvic3n55dNycXFZmorKVDatIRRYQ8X8oZJ0hHDLBbeGaS4s7jSXuKoNIQQby5umbYUVzDJNeWc5OyuWO9_O6yu1CS4XslVeO3U74cNK6ZCL70HpzjJOmyYbUq6lltLUTHaCVTVvBKfZ6-3OazO1A3QGxhR0f2R6vDK6tVr5X0pWggk5G7y8Mwj-5wQxqcHFuU96BD9FRSvc8AoLjjP6_C_0yk9hzK3KFCGMMFkfUCudD-BG6_O-ZjZVF5WsOMVCsEyd_4PKbweDM_l2rMvzR4JXR4LMJLhJKz3FqJbfvh6zLw7YNeg-raPvp5SDFI9BugNN8DEGsPvGEazmPKtdnlXOs7rNs5pFzw5bvpf8CXAGXu-Aa2i9jcbBaGCPYYzrHJo6X2l-SKbl_9MLl_R8ioWfxsR-AzGuDZA</recordid><startdate>20211208</startdate><enddate>20211208</enddate><creator>Wang, Wei</creator><creator>Li, Yan</creator><creator>Ali, Haval</creator><creator>Zhao, Linjun</creator><creator>Mei, Di</creator><creator>Hu, Wenqing</creator><creator>Jiang, Bin</creator><general>Springer Nature</general><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211208</creationdate><title>Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens</title><author>Wang, Wei ; Li, Yan ; Ali, Haval ; Zhao, Linjun ; Mei, Di ; Hu, Wenqing ; Jiang, Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c628t-9bc12e3925e392281d114f454fc3a45f0da48067c1110cf499bb5f53f3a24df43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>B cells</topic><topic>B-cell non-Hodgkin lymphoma</topic><topic>Biopsy</topic><topic>Bone marrow</topic><topic>Bone Marrow Cells - chemistry</topic><topic>Bone Marrow Cells - metabolism</topic><topic>Bone marrow examination</topic><topic>Bone marrow involvement</topic><topic>Burkitt's lymphoma</topic><topic>Care and treatment</topic><topic>CD54</topic><topic>Cell differentiation</topic><topic>Chronic lymphocytic leukemia</topic><topic>Complications and side effects</topic><topic>Diagnosis</topic><topic>Female</topic><topic>Flow Cytometry</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Intercellular Adhesion Molecule-1 - analysis</topic><topic>Intercellular Adhesion Molecule-1 - metabolism</topic><topic>Life Sciences & Biomedicine</topic><topic>Light</topic><topic>Lymphatic leukemia</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Lymphoma, B-Cell - metabolism</topic><topic>Lymphoma, B-Cell - pathology</topic><topic>Male</topic><topic>Mantle cell lymphoma</topic><topic>Measurement</topic><topic>Middle Aged</topic><topic>Non-Hodgkin's lymphoma</topic><topic>Non-Hodgkin's lymphomas</topic><topic>Oncology</topic><topic>Plasma</topic><topic>Science & Technology</topic><topic>Statistical analysis</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Ali, Haval</creatorcontrib><creatorcontrib>Zhao, Linjun</creatorcontrib><creatorcontrib>Mei, Di</creatorcontrib><creatorcontrib>Hu, Wenqing</creatorcontrib><creatorcontrib>Jiang, Bin</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Wei</au><au>Li, Yan</au><au>Ali, Haval</au><au>Zhao, Linjun</au><au>Mei, Di</au><au>Hu, Wenqing</au><au>Jiang, Bin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens</atitle><jtitle>BMC cancer</jtitle><stitle>BMC CANCER</stitle><addtitle>BMC Cancer</addtitle><date>2021-12-08</date><risdate>2021</risdate><volume>21</volume><issue>1</issue><spage>1315</spage><epage>1315</epage><pages>1315-1315</pages><artnum>1315</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Background Flow cytometry (FC) is a popular method to detect bone marrow (BM) involvement in patients with B-cell non-Hodgkin lymphoma (B-NHL). The majority of screen panels of FC still rely on finding monoclonal B-cells, e.g., B-cells with immunoglobin (Ig) light-chain restriction, which has many limitations. Therefore, exploring new markers is warranted. Methods A total of 52 cases of B-NHL with BM involvement were collected. The median age was 60 years. Out of these 52 cases, 34 were male, and 18 were female. A 10-color FC panel was used to detect the expression of CD54 on lymphoma cells. The expression of CD54 was calculated as the mean fluorescence index ratio (MFIR) and was described as the mean +/- standard error of the mean (SEM). Results Up to 18/52 (34.62%) of BM specimens abnormally expressed an increased level of CD54, including 1/10 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 9/13 cases of mantle cell lymphoma (MCL), 2/14 cases of follicular lymphoma (FL), 5/9 cases of marginal zone lymphoma (MZL), and 1/3 cases of high-grade B-NHL (HG B-NHL). The expression level of CD54 was significantly increased in MCL cases (53.41 +/- 11.04) compared with CLL/SLL cases (11.66 +/- 2.79) and FL cases (13.49 +/- 2.81). The lowest percentage of CD54-positive B-cells attained 0.13%. In 5/9 cases of MZL and 1/3 cases of HG B-NHL, increased expression of CD54 was the only abnormal immunophenotype detected besides Ig light-chain restriction. No aberrant CD54 expression was identified by FC in lymphoplasmacytic lymphoma (LPL) (0/2) and Burkitt lymphoma (BL) (0/1) cases. Aberrant expression of CD54 was not related to plasma cell differentiation. Conclusion Lymphoma cells, especially in MCL and MZL cases, frequently show increased expression of CD54. Such aberrant expression is not related to plasma cell differentiation. We highly recommend adding CD54 to the FC screening panel to detect BM involvement in patients with B-NHL.</abstract><cop>LONDON</cop><pub>Springer Nature</pub><pmid>34879826</pmid><doi>10.1186/s12885-021-09061-3</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2407 |
| ispartof | BMC cancer, 2021-12, Vol.21 (1), p.1315-1315, Article 1315 |
| issn | 1471-2407 1471-2407 |
| language | eng |
| recordid | cdi_gale_healthsolutions_A686420553 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerNature Journals; PubMed Central Open Access; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central; Springer Nature OA/Free Journals |
| subjects | Adult Aged Aged, 80 and over Analysis B cells B-cell non-Hodgkin lymphoma Biopsy Bone marrow Bone Marrow Cells - chemistry Bone Marrow Cells - metabolism Bone marrow examination Bone marrow involvement Burkitt's lymphoma Care and treatment CD54 Cell differentiation Chronic lymphocytic leukemia Complications and side effects Diagnosis Female Flow Cytometry Humans Immunoglobulins Intercellular Adhesion Molecule-1 - analysis Intercellular Adhesion Molecule-1 - metabolism Life Sciences & Biomedicine Light Lymphatic leukemia Lymphocytes B Lymphoma Lymphoma, B-Cell - metabolism Lymphoma, B-Cell - pathology Male Mantle cell lymphoma Measurement Middle Aged Non-Hodgkin's lymphoma Non-Hodgkin's lymphomas Oncology Plasma Science & Technology Statistical analysis Variance analysis |
| title | Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T17%3A52%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aberrant%20expression%20of%20CD54%20detected%20by%20flow%20cytometry%20is%20a%20characteristic%20of%20B-lymphoma%20cells%20in%20bone%20marrow%20specimens&rft.jtitle=BMC%20cancer&rft.au=Wang,%20Wei&rft.date=2021-12-08&rft.volume=21&rft.issue=1&rft.spage=1315&rft.epage=1315&rft.pages=1315-1315&rft.artnum=1315&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-021-09061-3&rft_dat=%3Cgale_proqu%3EA686420553%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2611313870&rft_id=info:pmid/34879826&rft_galeid=A686420553&rft_doaj_id=oai_doaj_org_article_adf3429948024a8a88c738d536749542&rfr_iscdi=true |